Key clinical point: U.S. centers that performed the most TAVR procedures had the best rates of 30-day patient survival.
Major finding: The hospital quartile with the lowest TAVR volume had a 21% higher mortality rate relative to the highest-volume quartile.
Study details: Analysis of data from 113,622 TAVR procedures done at U.S. hospitals during 2015-2017.
Disclosures: Dr. Vemulapalli has received personal fees from Boston Scientific, Janssen, Novella, Premiere, and Zafgen, and he has received research funding from Abbott Vascular and Boston Scientific.
Vemulapalli S et al. N Engl J Med. 2019 Apr 3. doi: 10.1056/NEJMsa1901109.